Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
Condition(s)
Leukemia
Leukemia
Age Group
0-9 years 10-17 years 18-26 years
0-9 years 10-17 years 18-26 years
Phase(s)
1
1
Drug
Tocilizumab
Biological
CART 19
Trial Summary & Details
Ages: 1 Year to 24 Years
Condition: Lymphoblastic Leukemia, Acute, Childhood
Condition: Lymphoblastic Leukemia, Acute, Childhood
This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated cytokine release syndrome safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high versus low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).